The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML

Xspray Pharma, the developer of the drug dasatinib, was recently issued a Complete Response Letter (CRL) by the FDA while waiting for corrective actions, according to Cancer Network.  Based on…

Continue Reading The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML

Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples

Biomarker analysis plays a pivotal role in cancer care and research, guiding the development of targeted therapies and enabling personalized treatment plans. While next-generation sequencing (NGS) has revolutionized the ability…

Continue Reading Navigating the Challenges of Biomarker Testing in Oncology: Innovations for Low-Yield Samples

Early Research on Two Tough Cancers

Pancreatic cancer took Alex Trebek, Michael Landon, Ruth Bader Ginsburg, Luciano Pavarotti, Steve Jobs,  Patrick Swayze, and my dear friend Amy. Glioblastoma (GBM) took Senators John McCain and Ted Kennedy,…

Continue Reading Early Research on Two Tough Cancers

The Unspoken Guilt of Living

Editor's Note: Patient Worthy is honored to share this story from our friends at Elephants & Tea. To see the article in its original form, please click here. Original author…

Continue Reading The Unspoken Guilt of Living

And the Good News is . . .Cancer Survivors in the United States are Projected to Exceed 22 million people by 2035

Here's a more detailed explanation. The newest American Cancer Society study just released suggests that a diagnosis of cancer is no longer a death sentence. According to a recent U.S.…

Continue Reading And the Good News is . . .Cancer Survivors in the United States are Projected to Exceed 22 million people by 2035
Research Breakthrough: Scientists May Have Discovered How Tumor Cells Outwit the Immune System
source: pixabay.com

Research Breakthrough: Scientists May Have Discovered How Tumor Cells Outwit the Immune System

Editor's Note: Chronic conditions and rare diseases don't discriminate, Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have…

Continue Reading Research Breakthrough: Scientists May Have Discovered How Tumor Cells Outwit the Immune System
Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers
source: shutterstock.com

Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers

Carisma Therapeutics, the manufacturer of CT-0508, issued a press release stating that researchers are conducting a combination study using CAR-M cell therapy plus Keytruda (pembrolizumab) in the treatment of overexpressing…

Continue Reading Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers